


The group is a part of the Healthcare Research Institute of Santiago (IDIS), an institution that brings together the strengths of the University of Santiago with the clinical power of the Hospital Clínico Universitario de Santiago.



GENVIP group bets on the most innovative technologies focused on the biomarkers study in different fields of biomedicine and basic research. GENVIP provides genomic, transcriptomic and bioinformatic services through its own platforms: n-counter Nanostring ([www.nanostringenvip.com](http://www.nanostringenvip.com)), Next-Seq ([www.genvipnextseq.com](http://www.genvipnextseq.com)) or Single-Cell transcriptomics.

GENVIP therefore has considerable experience in a wide range of techniques for cell biology, CRISPR-Cas9 gene editing, massive genotyping, next generation sequencing and bioinformatic data analysis.



**Genetics, Vaccines  
Infectious Diseases and  
Pediatrics Research Group**

[genvip.idis@gmail.com](mailto:genvip.idis@gmail.com)  
[www.genvip.eu](http://www.genvip.eu)

[nanostringenvip.com](http://nanostringenvip.com)  
[genvipnextseq.com](http://genvipnextseq.com)  
[dia-vir.com](http://dia-vir.com)



@GENVIP\_RESEARCH



[linkedin.com/company/nanostringenvip](https://www.linkedin.com/company/nanostringenvip)



**Genetics, Vaccines  
Infectious Diseases and  
Pediatrics Research Group**

[www.genvip.org](http://www.genvip.org)



GENVIP is a clinical and translational research group in infectious diseases and vaccines using an “omic” approach. GENVIP has a world class fully professional clinical trial unit for vaccines and anti-infectious drugs from design to trial performance. GENVIP has received several excellence recognitions, including the I International ZENDAL award.

GENVIP is fully integrated in the Translational Pediatrics and Infectious Diseases section of the Hospital Clínico Universitario de Santiago, (awarded Best Infectious Diseases Unit of Spain for 3 consecutive years).

The team is based in Santiago de Compostela, a historic town with a strong cultural background and university tradition.

## The team

The team is led by Prof. Federico Martinon-Torres, a paediatrician with substantial clinical and research experience in the field of infectious diseases, and Antonio Salas Ellacuriaga, at the School of Medicine and an internationally renowned geneticist. GENVIP has extensive collaborative experience in large scale multicentre studies related to infectious diseases and “omics”.




This is shown in + 600 publications and + 100 competitive research projects, and the leadership of different national and international consortia, providing international visibility and prestige to research conducted in Spain.

GENVIP aims to consolidate its position at forefront of international research on infectious diseases and vaccines. GENVIP is committed to continuing collaboration with a wide range of research groups worldwide and to play an important role in the battle against infectious diseases.

## Who are we?

GENVIP is a young and multidisciplinary team of pediatricians, geneticists, pharmacists, immunologists, bioinformaticians and mathematicians) that engages a large number of early- and mid-career researchers who combine energy and dynamism with rigour, ingenuity and a truly groundbreaking, international agenda.



## Clinical Trials Unit

GENVIP has created a world-class clinical trial unit with fully dedicated staff, mainly focused on vaccines and antimicrobials development.

This unit channels a large proportion of the clinical trials carried out in Spain for vaccines, from phase 1 with more than 100 trials for 60 different vaccine candidates performed so far. Furthermore, it collaborates with several sponsors in the design of protocols and clinical development programs for a range of vaccine candidates , as well as the search for biomarkers of protection and evaluation of real world epidemiological impact.



**WHO collaborating centre:** GENVIP coordianates the WHO Collaborating Centre for Vaccine Safety of Santiago de Compostela since 2016.

## Our mission

GENVIP mission is to perform high quality research, to expand the knowledge of infectious diseases and to improve its diagnosis, and to develop safe and effective therapeutic and preventive interventions.

## Networking and biobanking

GENVIP has established a number of national and international clinical networks of paediatric patients. This work is allowing the collection of numerous clinical data as well as the creation of an important Biobank – both of them key for the development of further clinical scientific research.




GENVIP has vast experience in large consortia and clinical networks management (ESIGEM, GENDRES, ROTACOST, REGALIP or MENDICOS), EU-FP7 projects (EUCLIDS and PREPARE), H2020 Projects (Poc-ID, ZIKACTION, PERFORM and DIAMONDS), and IMI2 Projects (RESCEU, PROMISE and C4C).

GENVIP also coordinates the Spanish Pediatric Clinical Trials Network (RECLIP; [www.reclip.org](http://www.reclip.org)) Translational Research Network in Pediatric Infectious Diseases (RITIP; [www.ritip.org](http://www.ritip.org)), cluster of networks under development.



GENVIP now belongs to the Spanish Consortium of Research in Network for Respiratory Diseases of the Instituto Carlos III (CIBERES)



## Our vision

GENVIP vision is to integrate clinical and research expertise in a breakthrough translational approach with the aim of decreasing the global burden of infections and providing personalized solutions to the individual patient.



### Prof. Federico Martinón-Torres

“So far we have focused primarily on the host approach to understand infectious diseases, with special attention to meningococci, pneumococci, rotavirus or respiratory viruses (RSV, SARS-COV-2...) through different international multi-centre approaches. We are also working on biomarkers search and its translation to clinical practice (PoC-ID, DIAVIR,...). All funded through competitive EU grants as well as FEDER funds through the Instituto de Salud Carlos III.”



### Prof. Antonio Salas

“The group has implemented the most cutting-edge methodology in the field of molecular biology and genomics, with a main focus on personalized medicine. Thus, we are now at the vanguard of ‘omic’ sciences, by incorporating immunosequencing and single cell-based ‘omic’ studies to our more familial fields of research in genomics, transcriptomics, proteomics, and epigenomics. In parallel to these developments, we have consolidated our local computational servers. Much more relevant is the multidisciplinary nature of our specialized team that have incorporated bioinformaticians, mathematicians, geneticists, programmers, cell biologists, etc.”